INT37485

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 1984
Last Reported 2011
Negated 5
Speculated 3
Reported most in Body
Documents 10
Total Number 12
Disease Relevance 6.64
Pain Relevance 1.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (RAPGEF5) intracellular (RAPGEF5)
Anatomy Link Frequency
blood 3
urine 2
glomerular mesangium 1
Kidney 1
RAPGEF5 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 29 100.00 Very High Very High Very High
Pain 11 99.92 Very High Very High Very High
narcan 7 98.34 Very High Very High Very High
cINOD 20 89.44 High High
Catecholamine 4 89.44 High High
aspirin 4 87.76 High High
Calcium channel 3 86.72 High High
Endogenous opioid 2 78.88 Quite High
Angina 2 72.40 Quite High
beta blocker 3 68.48 Quite High
Disease Link Frequency Relevance Heat
Nicotine Addiction 93 100.00 Very High Very High Very High
INFLAMMATION 34 100.00 Very High Very High Very High
Disorders Of Creatine Metabolism 22 100.00 Very High Very High Very High
Pain 16 99.92 Very High Very High Very High
Pressure Volume 2 Under Development 5 97.88 Very High Very High Very High
Hypertension 25 96.16 Very High Very High Very High
Polycystic Kidney Disease 12 95.14 Very High Very High Very High
Increased Venous Pressure Under Development 15 94.80 High High
Autosomal Dominant Polycystic Kidney 111 94.64 High High
Appetite Loss 4 93.48 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In a double-blind complete crossover study of blood pressure and renal function in hypertensive patients controlled with timolol-hydrochlorothiazide, sulindac lowered blood pressure significantly, whereas naproxen and piroxicam significantly raised blood pressure, in the absence of any effect on GFR, plasma renin, weight, creatinine clearance, or urinary sodium.
Regulation (effect) of GFR in blood associated with pressure volume 2 under development, disorders of creatine metabolism and hypertension
1) Confidence 0.44 Published 1986 Journal Scand. J. Rheumatol. Suppl. Section Abstract Doc Link 3541167 Disease Relevance 0.79 Pain Relevance 0.37
In normal man these drugs appear not to affect GFR and RBF.
Neg (not) Regulation (affect) of GFR
2) Confidence 0.23 Published 1984 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 6442643 Disease Relevance 0.07 Pain Relevance 0.07
PGE2 and PGI2 may regulate GFR and RBF by modulating either the vasoconstrictor actions on arterioles or the contractile activity of these agents on the glomerular mesangium.
Spec (may) Regulation (regulate) of GFR in glomerular mesangium
3) Confidence 0.23 Published 1984 Journal Clin. Exp. Rheumatol. Section Abstract Doc Link 6442643 Disease Relevance 0.07 Pain Relevance 0.07
However, because we found cadmium-associated effects on NAG and protein HC even in never-smokers, and there was no effect of smoking on creatinine clearance or GFR, this is unlikely.
Neg (no) Regulation (effect) of GFR associated with nicotine addiction and disorders of creatine metabolism
4) Confidence 0.22 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1310929 Disease Relevance 0.64 Pain Relevance 0
HOI during concomitant naloxone administration had similar effects on MAP and humoral factors, however, caused no change in GFR, ERPF and renal blood flow, and the fall in renal vascular resistance, from 98 +/- 6 to 83 +/- 5 mm Hg.min.liter-1 (P < 0.05) was significantly less than found in the absence of naloxone (P < 0.05).
Neg (no) Regulation (change) of GFR in blood associated with narcan
5) Confidence 0.21 Published 1995 Journal Kidney Int. Section Abstract Doc Link 7474676 Disease Relevance 0.32 Pain Relevance 0.45
Smoking should be considered as a cause of increased REE in patients with CKD when analyzing the effect of other variables such as inflammation and GFR.
Spec (analyzing) Regulation (effect) of GFR associated with nicotine addiction and inflammation
6) Confidence 0.17 Published 2005 Journal BMC Nephrol Section Body Doc Link PMC1308817 Disease Relevance 1.71 Pain Relevance 0.09
They showed that nesiritide did not affect GFR, renal plasma flow, urine output, or sodium excretion [40].
Neg (not) Regulation (affect) of GFR in urine
7) Confidence 0.16 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC3010630 Disease Relevance 1.29 Pain Relevance 0
The objective of this pharmacodynamic study was to evaluate the effects of low to moderate doses of vasopressin on renal blood flow (RBF), glomerular filtration rate (GFR), renal oxygen consumption (RVO2) and renal oxygen extraction (RO2Ex) in post-cardiac surgery patients.
Regulation (effects) of GFR in blood
8) Confidence 0.16 Published 2009 Journal Acta Anaesthesiol Scand Section Abstract Doc Link 19572935 Disease Relevance 0.26 Pain Relevance 0.04
These data demonstrate that both the GFR and renin responses to furosemide are altered during ontogeny.
Regulation (altered) of GFR
9) Confidence 0.15 Published 1995 Journal Can. J. Physiol. Pharmacol. Section Abstract Doc Link 7600440 Disease Relevance 0.17 Pain Relevance 0.10
GFR was not affected either by celecoxib alone or by combined administration with irbesartan.
Neg (not) Regulation (affected) of GFR
10) Confidence 0.09 Published 2001 Journal Swiss Med Wkly Section Body Doc Link 11345810 Disease Relevance 0 Pain Relevance 0
A controlled trial, the Halt Progression of Polycystic Kidney Disease study (NCT00283686), funded by the National Institutes of Health, is under way to determine whether treatment with ACE inhibitors and ARBs, administered singly or in combination, will reduce the rate of increase in kidney volume and slow the decline in GFR [25].
Spec (whether) Regulation (decline) of GFR in Kidney associated with polycystic kidney disease
11) Confidence 0.03 Published 2011 Journal International Journal of Nephrology Section Body Doc Link PMC3017903 Disease Relevance 1.03 Pain Relevance 0.15
The objective of the current study was to compare the efficacy of agalsidase alfa and beta at an equal dose of 0.2 mg/kg given once every two weeks, in Fabry patients with respect to 1. decrease in cardiac mass 2. changes in GFR, pain and GL-3 in serum and urine 3. number of treatment failures.


Regulation (changes) of GFR in urine associated with pain
12) Confidence 0.01 Published 2007 Journal PLoS ONE Section Body Doc Link PMC1913555 Disease Relevance 0.27 Pain Relevance 0.14

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox